Yahoo
NYSEArca - Nasdaq Real Time Price USD

ProShares S&P Kensho Cleantech ETF (CTEX)

33.26 0.00 (0.00%)
As of 9:46:03 AM EDT. Market Open.
Trade CTEX on Coinbase
Chart Range Bar
Loading chart for CTEX
  • Previous Close 33.26
  • Open 33.00
  • Bid 32.45 x 40000
  • Ask 32.50 x 10000
  • Day's Range 33.26 - 33.76
  • 52 Week Range 26.27 - 51.50
  • Volume 150
  • Avg. Volume 1,264
  • Net Assets 5.04M
  • NAV 33.35
  • PE Ratio (TTM) 21.22
  • Yield 2.19%
  • YTD Daily Total Return -5.56%
  • Beta (5Y Monthly) 2.27
  • Expense Ratio (net) 0.58%

The fund invests in financial instruments that ProShare Advisors believes, in combination, should track the performance of the index. The index is designed to measure the performance of U.S.-listed companies focused on building the technologies or products that enable the generation of clean energy, such as solar, wind, geothermal, hydrogen, and hydroelectric. The fund will invest in all of the component securities of the index in approximately the same proportion as the index. It is non-diversified.

ProShares

Fund Family

Technology

Fund Category

5.04M

Net Assets

2021-09-29

Inception Date

Performance Overview

View More

Trailing returns as of 8/21/2026. Category is Technology.

YTD Return

CTEX
5.56%
Category
13.51%

1-Year Return

CTEX
34.90%
Category
54.99%

3-Year Return

CTEX
7.17%
Category
27.86%

People Also Watch

Holdings

View More

Top 9 Holdings (39.39% of Total Assets)

Symbol Company % Assets
FuelCell Energy, Inc. 5.60%
Arcosa, Inc. 5.57%
GE Vernova Inc. 4.38%
Canadian Solar Inc. 4.28%
First Solar, Inc. 4.27%
Shoals Technologies Group, Inc. 4.24%
ReNew Energy Global Plc 3.83%
Generac Holdings Inc. 3.62%
Enphase Energy, Inc. 3.61%

Sector Weightings

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 08/24/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Moderna and Merck: Intismeran's Positive Phase 3 Readout Confirms mRNA Potential in Oncology

    Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

    Rating
    Price Target
  • 3M Earnings: Strong New Product Sales Propel Organic Growth, but Already Baked Into Our Valuation

    3M, a multinational conglomerate founded in 1902, sells tens of thousands of products ranging from sponges to respirators. The firm is well known for its extensive research and development capabilities and is a pioneer in inventing new uses for its proprietary technologies. 3M has three business segments: safety and industrial (around 44% of revenue), transportation and electronics (36%), and consumer (20%). The firm recently spun off its healthcare business, now known as Solventum. Nearly half of 3M’s revenue comes from outside the Americas.

    Rating
    Price Target
  • Incyte Earnings: Strong Opzelura Sales, Positive Povorcitinib Data as Jakafi Patent Loss Approaches

    Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

    Rating
    Price Target

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: